Delisting, Listing Rule Failure, or Listing Transfer

Business Context and Reporting Period

This Form 8-K is a current report filed by Coeptis Therapeutics Holdings, Inc. (not Z Squared Inc.) on January 12, 2026. The registrant is incorporated in Delaware and its common stock (COEP) and warrants (COEPW) trade on the Nasdaq Capital Market. The report addresses a regulatory compliance issue regarding the company's listing status.

Key Financial Metrics

The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and listing compliance matters.

Material Changes and Events

  • Nasdaq Delisting Notice: On January 12, 2026, the company received a letter from Nasdaq indicating a violation of Listing Rules 5620(a) and 5810(c)(2)G).
  • Reason for Violation: Failure to hold an annual meeting of shareholders within twelve months of the fiscal year-end (December 31, 2024).
  • Compliance Timeline: The company has 45 calendar days to submit a plan to regain compliance. If accepted, Nasdaq may grant an extension up to June 29, 2026.
  • Proposed Resolution: The company is scheduled to hold its annual meeting on January 30, 2026, which management believes will satisfy the Annual Meeting Rule.

Guidance, Outlook, and Risks

The filing contains forward-looking statements regarding the company's ability to regain compliance with Nasdaq listing rules. Management expresses the belief that the scheduled January 30, 2026, annual meeting will be sufficient to resolve the violation. However, the report explicitly states that these statements are not guarantees and are subject to risks and uncertainties that could cause actual results to vary materially.

Investor Verification Checklist

  • Confirm the date and outcome of the annual shareholder meeting scheduled for January 30, 2026.
  • Monitor Nasdaq's official response to the company's compliance plan submission.
  • Verify the continued listing status of COEP and COEPW on the Nasdaq Capital Market.
  • Review the previously filed Form S-4 (dated January 5, 2026) for details on the proxy statement and meeting logistics.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.